{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:48:17Z","timestamp":1784306897884,"version":"3.55.0"},"reference-count":130,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In order to increase the effectiveness of cancer therapies and extend the long-term survival of patients, more and more often, in addition to standard treatment, oncological patients receive also targeted therapy, i.e., CAR-T cells. These cells express a chimeric receptor (CAR) that specifically binds an antigen present on tumor cells, resulting in tumor cell lysis. The use of CAR-T cells in the therapy of relapsed and refractory B-type acute lymphoblastic leukemia (ALL) resulted in complete remission in many patients, which prompted researchers to conduct tests on the use of CAR-T cells in the treatment of other hematological malignancies, including acute myeloid leukemia (AML). AML is associated with a poorer prognosis compared to ALL due to a higher risk of relapse caused by the development of resistance to standard treatment. The 5-year relative survival rate in AML patients was estimated at 31.7%. The objective of the following review is to present the mechanism of action of CAR-T cells, and discuss the latest findings on the results of anti-CD33, -CD123, -FLT3 and -CLL-1 CAR-T cell therapy, the emerging challenges as well as the prospects for the future.<\/jats:p>","DOI":"10.3390\/cancers15112944","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:17:33Z","timestamp":1685204253000},"page":"2944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia\u2014Recent Advances"],"prefix":"10.3390","volume":"15","author":[{"given":"Julia","family":"Zarychta","sequence":"first","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kowalczyk","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1158\/1078-0432.CCR-21-1804","article-title":"Cancer Immunoediting in the Era of Immuno-oncology","volume":"28","author":"Gubin","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5114\/ceji.2022.117376","article-title":"Cancer immunoediting hypothesis: History, clinical implications and controversies","volume":"47","author":"Lasek","year":"2022","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110638","DOI":"10.1016\/j.cellsig.2023.110638","article-title":"CAR T-cell therapy: Reprogramming patient\u2019s immune cell to treat cancer","volume":"105","author":"Mavi","year":"2023","journal-title":"Cell Signal."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","article-title":"Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, Y.-J., Abila, B., and Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15.","DOI":"10.3390\/cancers15030663"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in Universal CAR-T Cell Therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Theresa, H., Greil, R., Zaborsky, N., and Geisberger, R. (2021). CAR T-Cell Therapy in Hematological Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168996"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CM9.0000000000002476","article-title":"Challenges and optimal strategies of CAR T therapy for hematological malignancies","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109593","DOI":"10.1016\/j.intimp.2022.109593","article-title":"The signaling and the metabolic differences of various CAR T cell designs","volume":"114","author":"Razavi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vishwasrao, P., Li, G., Boucher, J.C., Smith, D.L., and Hui, S.K. (2022). Emerging CAR T Cell Strategies for the Treatment of AML. Cancers, 14.","DOI":"10.3390\/cancers14051241"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","first-page":"38","article-title":"Acute Myeloid Leukemia: A Review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"Rhode Isl. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/curroncol29090491","article-title":"Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology","volume":"29","author":"Stubbins","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12098-015-1695-5","article-title":"Leukemias in Children","volume":"82","author":"Seth","year":"2015","journal-title":"Indian J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ped.12865","article-title":"Acute myeloid leukemia in children: Current status and future directions","volume":"58","author":"Taga","year":"2016","journal-title":"Pediatr. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cll.2017.07.003","article-title":"Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis","volume":"37","author":"Chen","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_19","unstructured":"U.S. Department of Health and Human Services, and National Cancer Institute (2023, May 18). Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html?fbclid=IwAR0_GxaUkdmDIG4fnflPQavtT48dpoYQQQBt3wOyfbIaJBiaQBo9LKkWaPI."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12185-012-1151-5","article-title":"Novel agents in acute myeloid leukemia","volume":"96","author":"Ungewickell","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41375-020-0719-y","article-title":"Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells","volume":"34","author":"Danylesko","year":"2020","journal-title":"Leukemia"},{"key":"ref_22","first-page":"188","article-title":"The expression of CD19 in 210 cases of childhood acute leukemia and its significance","volume":"42","author":"Chen","year":"2004","journal-title":"Chin. J. Pediatr."},{"key":"ref_23","first-page":"1360","article-title":"Clinical Features and Prognosis of 188 Patients with Acute Myeloid Leukemia-M2","volume":"27","author":"Wang","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: Current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1016\/j.clml.2020.05.004","article-title":"A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML","volume":"20","author":"Das","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34056","DOI":"10.18632\/oncotarget.26118","article-title":"Survival outcomes of CD34+CD38-LSCs and their expression of CD123 in adult AML patients","volume":"9","author":"Zahran","year":"2018","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple Signaling Roles of CD3\u03b5 and Its Application in CAR-T Cell Therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"797440","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"ref_42","unstructured":"U.S. Food & Drug Administration (2023, April 20). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"Heiber","year":"2015","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2017.241","article-title":"CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype","volume":"29","author":"Li","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12967-023-04041-6","article-title":"Tuning CARs: Recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility","volume":"21","author":"Celichowski","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: A novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2021-152692","article-title":"Phase 1\/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"El Achi, H., Dupont, E., Paul, S., and Khoury, J.D. (2020). CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113087"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2013.03.002","article-title":"Signalling by the \u03b2c family of cytokines","volume":"24","author":"Hercus","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.2147\/OTT.S205678","article-title":"IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Rettig","year":"2016","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells","volume":"11","author":"You","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"Hughes","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: The Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"ref_66","first-page":"650","article-title":"Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor \u00df towards B-Acute Myeloid Leukaemia Blasts","volume":"23","author":"Ghamari","year":"2021","journal-title":"Cell J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1945804","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kittel-Boselli, E., Soto, K.E.G., Loureiro, L.R., Hoffmann, A., Bergmann, R., Arndt, C., Koristka, S., Mitwasi, N., Kegler, A., and Bartsch, T. (2021). Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. Cancers, 13.","DOI":"10.3390\/cancers13194785"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., and Yakoub-Agha, I. (2021). Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13246157"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nitika Wei, J., and Hui, A.M. (2022). Role of Biomarkers in FLT3 AML. Cancers, 14.","DOI":"10.3390\/cancers14051164"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pedersen, M.G., M\u00f8ller, B.K., and Bak, R.O. (2022). Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102441"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: Synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/leu.2017.147","article-title":"Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Maiorova, V., Mollaev, M.D., Vikhreva, P., Kulakovskaya, E., Pershin, D., Chudakov, D.M., Kibardin, A., Maschan, M.A., and Larin, S. (2021). Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines. Vaccines, 9.","DOI":"10.3390\/vaccines9111238"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: The multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Laborda, E., Mazagova, M., Shao, S., Wang, X., Quirino, H., Woods, A.K., Hampton, E.N., Rodgers, D.T., Kim, C.H., and Schultz, P.G. (2017). Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112259"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.bbmt.2018.12.470","article-title":"Optimizing C-Type Lectin-like Molecule 1 (CLL-1) Directed CAR T Cell Therapy of Acute Myeloid Leukemia","volume":"25","author":"Atilla","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e001229","DOI":"10.1136\/jitc-2020-001229","article-title":"Modulating TNF\u03b1 activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia","volume":"8","author":"McKenna","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fonc.2020.00685","article-title":"Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med."},{"key":"ref_93","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04835519."},{"key":"ref_94","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05105152."},{"key":"ref_95","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03927261."},{"key":"ref_96","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318678."},{"key":"ref_97","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04272125."},{"key":"ref_98","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03190278."},{"key":"ref_99","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05432401."},{"key":"ref_100","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05445011."},{"key":"ref_101","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05023707."},{"key":"ref_102","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05017883."},{"key":"ref_103","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05252572."},{"key":"ref_104","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04923919."},{"key":"ref_105","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04219163."},{"key":"ref_106","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04789408."},{"key":"ref_107","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04884984."},{"key":"ref_108","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010877."},{"key":"ref_109","unstructured":"U.S. National Library of Medicine (2023, April 30). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05248685."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"755639","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR. CD19 T Cell Therapy in B-Cell Malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-022-01913-7","article-title":"RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function","volume":"40","author":"Zhu","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Motais, B., Charv\u00e1tov\u00e1, S., Hrdinka, M., \u0160im\u00ed\u010dek, M., Jel\u00ednek, T., \u0160ev\u010d\u00edkov\u00e1, T., Ko\u0159\u00edstek, Z., H\u00e1jek, R., and Bag\u00f3, J.R. (2020). A Bird\u2019s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers, 12.","DOI":"10.3390\/cancers12051333"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.beha.2019.101104","article-title":"How close are we to CAR T-cell therapy for AML?","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11864-023-01049-4","article-title":"Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies","volume":"24","author":"Cao","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Harrer, D.C., D\u00f6rrie, J., and Schaft, N. (2023). CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032342"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"109030","DOI":"10.1016\/j.clim.2022.109030","article-title":"The Tmod cellular logic gate as a solution for tumor-selective immunotherapy","volume":"241","author":"DiAndreth","year":"2022","journal-title":"Clin. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"121409","DOI":"10.1016\/j.lfs.2023.121409","article-title":"Explorations of CRISPR\/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy","volume":"316","author":"Naeem","year":"2023","journal-title":"Life Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ni0508-477","article-title":"Natural killer cell recognition of missing self","volume":"9","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1052717","DOI":"10.3389\/fimmu.2022.1052717","article-title":"Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/2944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:21Z","timestamp":1760125401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/11\/2944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":130,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cancers15112944"],"URL":"https:\/\/doi.org\/10.3390\/cancers15112944","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}